NCT03720223View on ClinicalTrials.gov

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Urethral Stricture
Interventions
DRUG

Liposomal Bupivacaine

20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)

Trial Locations (1)

23454

Urology of Virginia, Virginia Beach

All Listed Sponsors
lead

Urology of Virginia

OTHER

NCT03720223 - Liposomal Bupivacaine To Control Post-Operative Pain Following BMG | Biotech Hunter | Biotech Hunter